James Roosevelt Jr. named to Inverness board
WALTHAM, Mass. Inverness Medical Innovations on Monday named James Roosevelt, Jr., president and CEO of Tufts Health Plan, to the company’s board.
Roosevelt was recently selected by President Barack Obama as part of the administration’s transition team to co-chair a review of the Social Security Administration. He serves as chairman for Massachusetts Association of Health Plans, and as a member of the board at America’s Health Insurance Plans, Emmanuel College and the Kenneth B. Schwartz Center.
Study finds no cancer risks from hormone replacement therapy within first two years
ATLANTA The American Cancer Society last week announced that there may be a two-year “safe period” for the use of hormone replacement therapies estrogen and progesterone.
According to a recently published study, new findings on the role of hormone use on the risk of breast cancer confirmed that the use of estrogen plus progesterone increases the risk of both ductal and lobular breast cancer by far more than estrogen-only, but found that the increased risk for ductal cancers observed in long-term past users of hormone replacement therapy drops off substantially two years after hormone use is stopped. They also found the risk associated with use of estrogen and progesterone increases significantly and substantially within three years of beginning hormone use. The data showed no increased risk for women who used estrogen and progesterone for less than two years, potentially identifying a “safe” period for estrogen and progesterone use.
The study appears in CANCER, a peer-reviewed journal of the American Cancer Society.
Previous studies have shown that hormone replacement therapy after menopause increases the risk of breast cancer and that use of a regimen that includes both estrogen and progesterone is more detrimental for the breast than the use of estrogen alone. But more data from large prospective studies are needed to fully characterize the impact of exogenous hormones on breast cancer incidence by type of hormone preparation and histology of the cancer.
Hamacher Resource Group adopts ReadyTouch technology
MILWAUKEE Hamacher Resource Group on Monday announced an exclusive alliance with in-store kiosk pioneer ReadyTouch, a provider of retail marketing systems designed to seamlessly bring the latest product expertise to consumers at the point of decision.
ReadyTouch’s technology was first deployed to wine and spirit retailers, and the unique browser-based search capabilities are also ideally suited for retail health care, Hamacher stated. The ReadyTouch System leverages content management technology on an NCR hardware platform to enhance the consumer shopping experience, to allow product promotions and ultimately to boost retail ROI and sales.
“With increased focus on in-store influence and the overall shopping experience, we are extremely confident and excited about this new relationship that will allow innovative health, beauty and wellness retailers to step out of the shadow of conformity and into an era of leadership,” stated Dave Wendland, Hamacher VP.
“HRG is the ideal partner for us in retail healthcare,” stated Peter Bostwick, president and founder of ReadyTouch. “They have a thorough understanding of the market, enjoy an unprecedented level of respect and have a robust library of content that will enhance the consumer’s experience with our technology,” he said. “This kiosk system will bring efficiency, excitement and cost savings to shoppers, retailers, distributors and manufacturers of health, beauty and wellness products.”